Global WholeHealth Partners Corp.'s (OTC: GWHP) Antibody IgG/IgM and Antigen Tests That They Offer Are Capable of Detecting the DELTA B.1.617.2, United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) of COVID 19 SARS 2
SAN CLEMENTE, CA, July 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest line of Covid-19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses. The strains identified in DELTA B.1.617.2, United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein, Global understands the need to be ahead of the virus to conquer the virus.
The Biden administration is rethinking its approach to Covid-19 testing as the pandemic enters an uncertain phase…
But with newer variants like Delta circulating, the administration must also ensure that existing tests are capable of detecting emerging strains — and maintain enough testing capacity to detect and tamp down new bursts of infections. The government is working with the diagnostics industry to ensure the gains in domestic manufacturing are not lost over time. But it is not yet out of the danger zone with Covid-19. With public health experts warning that Delta could drive up cases in under-vaccinated areas, the Biden team is pushing ahead with plans to establish testing programs in schools and homeless shelters as the fall approaches. It is also pushing test makers to create products that can be used at home to simultaneously screen for flu, Covid and other common respiratory viruses.
Under Mr. Strongo’s direction, Global is following the President and his directions regarding COVID. To conquer COVID and win this war, Global must keep up the research and development of tests.
Mr. Strongo states, “Global continues to do research on all new strains of the COVID-19 virus to make sure the tests we offer are a useful and reliable diagnostic test."
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test
Global Wholehealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruse, and among other vector borne diseases. with an FDA Certificate of Exportability (2260-11-2019). The company was founded on March 7, 2013, and is headquartered in San Clemente, CA.
The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing. The adoption of a population-wide testing approach, which includes household, individual testing, is one of the trends influencing the demand for covid-19 diagnostics kits. The shift from symptomatic testing to mass testing in developed countries is another major factor affecting the market.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use, as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Currently, the Company offers 56 products FDA approved and many are Approved for OTC use, and 19 POC products approved by the CLIA WAIVED FDA.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Smart Street Lighting
Asset Management â€“ Keeping Remote Devices Connected
#TECHSUPERSHOW Expo Hall Grand Opening